drugset / Trial / NCT00513253

A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

NCT00513253

Phase 1 Withdrawn GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This study is designed to estimate the relative bioavailability of alternative lapatinib oral formulations compared to the current tablet formulation.

Timeline

Start
2008-04
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule Oral

Indications

No indication recorded.